

Patent EXAMPLES - Figures

I. BINDING OF METAL-IONS AND METAL-ION COMPLEXES TO VARIOUS DRUG TARGETS WITH NATURAL METAL-ION SITES

- I.1 Identification of naturally occurring metal-ion chelator binding site in the 7TM leukotriene LTB₄ receptor
- I.2 Identification of naturally occurring metal-ion chelator binding site in the 7TM galanin receptor
- I.3 Identification of naturally occurring metal-ion chelator binding site in a 12TM protein, the dopamine transporter.

II. BINDING OF METAL-ION COMPLEXES IN ENGINEERED METAL-ION SITES IN VARIOUS POTENTIAL DRUG TARGETS.

- II.1 Binding of various metal-ion complexes to a library of inter-helical metal-ion sites engineered into the tachykinin NK1 receptor
- II.2 Re-engineering of a metal-ion chelator binding site in the 12TM dopamine transporter.

III. INCREASING THE AFFINITY/POTENCY OF THE METAL-ION CHELATOR COMPLEXES THROUGH CHEMICAL MODIFICATIONS OF THE CHELATOR MOLECULE.

- III.1 Structure-activity relationship of antagonist metal-ion complexes in the galanin and the leukotrien LTB₄ receptors.
- III.2 Structure-activity relationship of antagonistic metal-ion complexes in the metal-ion site engineered tachykinin NK1 receptor.
- III.3 Structure-activity relationship of *agonist* metal-ion complexes in the metal-ion site engineered beta₂-adrenergic 7TM receptor.
- III.4 Structure-activity relationship of antagonistic metal-ion complexes in a soluble protein, the enzyme FVIIa.
- III.5 Structure-based optimisation of metal-ion chelators for secondary interactions in the CXCR4 receptor and other biological target molecules.
- III.6 Structure-based optimisation of metal-ion chelators to use as antagonists in 'pharmacological knock-out' experiments. *No figure !*

IV. OPTIMIZATION OF COMPOUNDS ON THE WILD-TYPE BIOLOGICAL TARGET MOLECULE *No figures !*

APPENDIX – List of compounds which appear in the Examples.